ArticleNature medicine1995
Marked amelioration of established collagen-induced arthritis by treatment with antibodies to CD23 in vivo.
Article in Nature medicine, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 64 citations in OpenAlex.
- A Comparison of Natural and Therapeutic Anti-IgE Antibodies.Antibodies (Basel, Switzerland) · 2024Review
- Activation of the P2X7 receptor induces the rapid shedding of CD23 from human and murine B cells.Immunology and cell biology · 2015Article
- Differential regulation of monocyte cytokine release by αV and β(2) integrins that bind CD23.Immunology · 2012Article
- IgE and mast cells in allergic disease.Nature medicine · 2012Review
- Human schistosome infection and allergic sensitisation.Journal of parasitology research · 2012Article
- The emergence of ADAM10 as a regulator of lymphocyte development and autoimmunity.Molecular immunology · 2011Review
- CD23/FcεRII: molecular multi-tasking.Clinical and experimental immunology · 2010Review
- When is a malaria immune complex not an immune complex?Parasite immunology · 2009Article
- Article
- The structure of human CD23 and its interactions with IgE and CD21.The Journal of experimental medicine · 2005Article
- Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis.The Journal of clinical investigation · 2001Article
- Increased synovial fluid levels of soluble CD23 are associated with an erosive status in rheumatoid arthritis (RA).Clinical and experimental immunology · 2000Article
- Expression of FCepsilonII/CD23 on human neutrophils isolated from rheumatoid arthritis patients.Inflammation · 1999Article
- The vitronectin receptor and its associated CD47 molecule mediates proinflammatory cytokine synthesis in human monocytes by interaction with soluble CD23.The Journal of cell biology · 1999Article
- Molecular analysis of rheumatoid factor (RF)-negative B cell hybridomas from rheumatoid synovial tissue: evidence for an antigen-induced stimulation with selection of high mutated IgVH and low mutated IgVL/lambda genes.Clinical and experimental immunology · 1999Article
- Inhibition of sCD23 and immunoglobulin E release from human B cells by a metalloproteinase inhibitor, GI 129471.Immunology · 1998Article
- Gene therapy for rheumatoid arthritis. Theoretical considerations.Drugs & aging · 1998Review
- Characterization of a constitutive type III nitric oxide synthase in human U937 monocytic cells: stimulation by soluble CD23.Immunology · 1997Article
- IL-10 suppresses cell surface CD23/Fc epsilon RII expression, not by enhancing soluble CD23 release, but by reducing CD23 mRNA expression in human monocytes.Journal of clinical immunology · 1996Article
- Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis.American journal of human genetics · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD23 is a low-affinity receptor for immunoglobulin E (IgE) expressed by a variety of haematopoietic cells. Proteolytic cleavage of the transmembrane receptor generates soluble forms, which can be detected in biological fluids. CD23 regulates many functional aspects of immune cells, both in its cell-associated and soluble forms. In view of the increased levels of CD23 in rheumatoid arthritis, we have studied the effect of neutralizing CD23 in type II collagen-induced arthritis in mice, a model for human rheumatoid arthritis. Successful disease modulation is achieved by treatment of arthritic DBA/1 mice with either polyclonal or monoclonal antibodies to mouse CD23. Treated mice show a dose-related amelioration of arthritis with significantly reduced clinical scores and number of affected paws. This improvement in clinical severity is confirmed by histological examination of the arthritic paws. A marked decrease in cellular infiltration of the synovial sublining layer and limited destruction of cartilage and bone is evident in animals treated with therapeutic doses of anti-CD23 antibody. These findings demonstrate the involvement of CD23 in a mouse model of human rheumatoid arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.